Opiant Pharmaceuticals, Inc. OPNT
We take great care to ensure that the data presented and summarized in this overview for OPIANT PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in OPNT
Top Purchases
Top Sells
About OPNT
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
Insider Transactions at OPNT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2023
|
Craig A Collard Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
55,822
-98.21%
|
$1,116,440
$20.0 P/Share
|
|
Mar 02
2023
|
Gabrielle Alison Silver Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
23,343
-95.72%
|
$466,860
$20.0 P/Share
|
|
Mar 02
2023
|
Richard J Daly Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,800
-87.18%
|
$156,000
$20.0 P/Share
|
|
Mar 02
2023
|
Matthew R. Ruth Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
31,916
-88.12%
|
$638,320
$20.0 P/Share
|
|
Mar 02
2023
|
Matthew R. Ruth Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+50.0%
|
-
|
|
Mar 02
2023
|
Mark Jason Heath Ellison Chief Development Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,751
-79.14%
|
$415,020
$20.0 P/Share
|
|
Mar 02
2023
|
Mark Jason Heath Ellison Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+50.0%
|
-
|
|
Mar 02
2023
|
Mark Jason Heath Ellison Chief Development Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
9,680
-100.0%
|
$193,600
$20.0 P/Share
|
|
Mar 02
2023
|
Roger Crystal Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
82,006
-83.23%
|
$1,640,120
$20.0 P/Share
|
|
Mar 02
2023
|
Roger Crystal Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,667
+50.0%
|
-
|
|
Mar 02
2023
|
Roger Crystal Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,100
-100.0%
|
$102,000
$20.0 P/Share
|
|
Mar 02
2023
|
Michael Sinclair Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
62,720
-100.0%
|
$1,254,400
$20.0 P/Share
|
|
Mar 02
2023
|
Michael Sinclair Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
27,450
-100.0%
|
$549,000
$20.0 P/Share
|
|
Mar 02
2023
|
Phil Skolnick Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
23,548
-81.85%
|
$470,960
$20.0 P/Share
|
|
Mar 02
2023
|
Phil Skolnick Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+50.0%
|
-
|
|
Mar 02
2023
|
Masuoka K. Lorianne Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,000
-75.0%
|
$80,000
$20.0 P/Share
|
|
Mar 02
2023
|
Ann L. Mac Dougall Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
28,179
-96.45%
|
$563,580
$20.0 P/Share
|
|
Mar 02
2023
|
Thomas T. Thomas Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,375
-91.92%
|
$247,500
$20.0 P/Share
|
|
Mar 02
2023
|
Brian Gorman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
33,990
-81.82%
|
$679,800
$20.0 P/Share
|
|
Mar 02
2023
|
Brian Gorman |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+50.0%
|
-
|